ClinicalTrials.gg

Program

mosliciguat

Also written as “Mosliciguat”, “inhaled mosliciguat” and “14C mosliciguat”.

Its studies are mostly in Hypertension, Pulmonary · Pulmonary Arterial Hypertension, led by 2 companies.

Furthest: phase 3, since Sep 7, 20265 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pulmovant43 open or runningphase 3since Sep 7, 2026Oct 8, 2024Dec 2026phase 2 · NCT07333183
Bayer10 open or runningphase 1since Nov 23, 2018Nov 23, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 23, 2018First study: phase 1 study in Hypertension, PulmonaryNew to BayerBayer · NCT03754660 · 38 enrolled · Austria, Czechia, Germany and more
  2. Oct 8, 2024Pulmovant's first study: phase 2 study in Hypertension, PulmonaryNew to PulmovantPulmovant · NCT06635850 · 135 enrolled · United States, Argentina, Australia and more
  3. Sep 12, 2025Phase 1 study in Healthy VolunteerPulmovant · NCT07185321 · 8 enrolled · United States
  4. Jan 8, 2026Phase 2 study in Hypertension, PulmonaryPulmovant · NCT07333183 · 20 planned · United States
  5. Sep 7, 2026Phase 3 study in Hypertension, PulmonaryPhase 3 reachedPulmovant · NCT07816185 · 376 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Hypertension, PulmonaryPulmovant · NCT07333183
  2. Jan 28, 2029Primary completion: phase 3 study in Hypertension, PulmonaryPulmovant · NCT07816185

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07816185Hypertension, Pulmonary · United States3RecruitingPulmovantJan 28, 2029376
NCT07333183Hypertension, Pulmonary · United States2RecruitingPulmovantDec 202620
NCT07185321Healthy Volunteer · United States1CompletedPulmovantJun 30, 20258
NCT06635850Hypertension, Pulmonary · United States, Argentina, Australia and more2Active, not recruitingPulmovantMay 26, 2026135
NCT03754660Hypertension, Pulmonary · Austria, Czechia, Germany and more1CompletedBayerApr 24, 202238

How it is read

Names in the registry

  • “Mosliciguat”, 3 entries
  • “inhaled mosliciguat”, 1 entry
  • “14C mosliciguat”, 1 entry
  • “BAY1237592”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.